Replies to post #61 on Roivant Sciences (ROIV)

[aries4747]

SIOX pre-market move. ROIV owns 25%.

https://www.globenewswire.com/news-release/2021/10/04/2307996/0/en/UPDATE-Sio-Gene-Therapies-to-Present-New-Data-at-the-European-Society-of-Gene-and-Cell-Therapy-Virtual-Congress-2021.html

Abstracts out from ESGCT:
Collaborative Virtual Congress
19–22 October 2021
https://www.liebertpub.com/doi/full/10.1089/hum.2021.29180.abstracts

ROIV stake in SIOX
https://investors.siogtx.com/investors/stock-information/institutional-ownership

[aries4747]

ROIV-related SIOX receives FDA Fast Track Designation for drug. ROIV owns 25% of SIOX.

https://www.globenewswire.com/news-release/2021/10/21/2318287/0/en/Sio-Gene-Therapies-Announces-Granting-of-FDA-Fast-Track-Designation-for-Investigational-AXO-AAV-GM1-AAV9-GLB1-Gene-Therapy-in-Patients-with-GM1-Gangliosidosis.html

[aries4747]

ROIV up 20% pm. Not because of ABUS patent, but on 3 analysts jumping on board with targets between $10 and $15.

https://www.streetinsider.com/Analyst+Comments/Roivant+Sciences+%28ROIV%29+Stock+Surges+20%25+as+Three+Street+Firms+Initiate+Coverage+With+Positive+Ratings/19104874.html